
Michael R. Charlton, MD, MBBS, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma.

Your AI-Trained Oncology Knowledge Connection!


Michael R. Charlton, MD, MBBS, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma.

Michael R. Charlton, MD, MBBS, discusses different types of therapy and trials in the hepatocellular carcinoma setting right now.

Published: April 16th 2020 | Updated: